Regulation - Asia-Pacific, Respiratory and Pulmonary

Filter

Popular Filters

Kyorin expects $10 million sales after Flutiform launch in Japan for asthma

Kyorin expects $10 million sales after Flutiform launch in Japan for asthma

19-11-2013

UK drug delivery specialist Skyepharma (LSE: SKP) has announced that Flutiform has been launched in Japan…

Asia-PacificFlutiformKyorin PharmaceuticalsLicensingPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

Flutiform recommended for approval in Japan

01-08-2013

UK drug delivery specialist Skyepharma (LSE SKP) revealed yesterday (July 31) that the Pharmaceutical…

Asia-PacificFlutiformKyorin PharmaceuticalsPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

GlaxoSmithKline and Theravance withdraw Japan NDA for Relvar Ellipta in COPD

12-07-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) revealed on Friday…

Asia-PacificBiotechnologyGlaxoSmithKlinePharmaceuticalRegulationRelvar ElliptaRespiratory and PulmonaryTheravance

GlaxoSmithKline and Theravance file for Japanese approval of Anoro Ellipta

22-04-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) today April 22) announced…

Anoro ElliptaAsia-PacificGlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryTheravance

Japanese approval for Actelion's epoprostenol "ACT"

19-02-2013

Europe's largest biotech firm Actelion (SIX: ATLN) yesterday announced that Japan's Ministry of Health,…

ActelionAsia-PacificBiotechnologyepoprostenol "ACT"RegulationRespiratory and PulmonaryVeletri

New Zealand approves funding of sildenafil for Raynaud's phenomenon and bosentan for children with PAH

28-01-2013

New Zealand's Pharmaceutical Management Agency PHARMAC has approved proposals for funding Pfizer's (NYSE:…

ActelionAsia-PacificBiotechnologybosentanFinancialPfizerPharmaceuticalRegulationRespiratory and PulmonaryRevatiosildenafilTracleer

New Zealand updates on Tracleer and sildenafil listing

21-11-2012

New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval of an agreement with…

ActelionArrow PharmaceuticalsAsia-PacificPharmaceuticalPricingRegulationRespiratory and PulmonarysildenafilTracleer

Proposal in relation to Actelion's Tracleer in New Zealand

01-10-2012

New Zealand's national pharmaceuticals funding agency PHARMAC is seeking feedback on a proposal in relation…

ActelionAsia-PacificBiotechnologyPricingRegulationRespiratory and PulmonaryTracleer

Japanese approvals for Eylea, Tresiba, Seebri and Aimix

01-10-2012

There was a flurry of announcements from Japan's Ministry of Health, Labor and Welfare (MHLW) on Friday,…

AimixAsia-PacificBayerCardio-vascularDainippon Sumitomo PharmaDiabetesEyleaNovartisNovo NordiskOphthalmicsPharmaceuticalRegeneronRegulationRespiratory and PulmonarySeebri BreezhalerShionogiTresibaVectura

US FDA accepts GSK and Theravance NDA for FF/VI; COPD drug filed in Japan

27-09-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) say that the New…

Asia-PacificfuroateGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTheravancevilanterol

SkyePharma partner Kyorin files for Flutiform approval in Japan

26-09-2012

UK drug delivery specialist SkyePharma (LSE: SKP) says that its Japanese development and marketing partner…

Asia-PacificFlutiformKyorin PharmaceuticalsNapp PharmaceuticalsPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

Shionogi partner Ildong gains South Korean approval for Pirespa

14-08-2012

Japanese drug major Shionogi (TYO: 4507) says that its South Korean partner Ildong Pharma has received…

Asia-PacificIldong PharmaPharmaceuticalPirespapirfenidoneRegulationRespiratory and PulmonaryShionogi

SkyePharma partner Kyorin completes Japanese Flutiform clinical program

26-06-2012

UK drug delivery specialist SkyePharma (LSE: SKP) saw its shares leap nearly 11% to £76.50 last…

Asia-PacificFlutiformKyorin PharmaceuticalsPharmaceuticalRegulationResearchRespiratory and PulmonarySkyepharma

Novartis and Vectura COPD drug candidate NVA237 filed for approval in Japan

28-11-2011

The Japanese subsidiary of Swiss drug major Novartis (NOVO: VX) has filed an application for sales and…

Asia-PacificFinancialNovartisPharmaceuticalRegulationRespiratory and PulmonarySeebriVectura

Parexel

Parexel

Back to top